Skip to main content

Genome-based biomarkers leading to validated molecular diagnostic tests for response prediction in breast cancer

Objective

Individualisation of cancer therapy based on standardized biomarker assays is one of the most demanding challenges in cancer medicine. In the RESPONSIFY consortium, we will integrate information on response prediction from different breast cancer types and methodologies into biomarker tests for targeted therapies in the clinical routine setting. Those tests will be developed for commercialisation using the expertise of the involved SMEs and industrial partners.
To reach this aim, we will use different genome based strategies to identify and characterise new biomarkers as well as validate biomarkers from previous projects. Genome based strategies include new molecular techniques such as genome wide next generation sequencing, epigenetics, gene and exon expression analysis, as well as kinome arrays, in-situ proteomics and quantitative PCR using FFPE tissue. A clearly defined marker finding-training-validation-approach will be the backbone of RESPONSIFY to reach a high level of evidence for commercial diagnostic tests. The established therapy stratification criteria will be further validated within clinical trials using the expertise of the clinical study groups.
The clinical study group will develop a web-based data integration and processing system to standardise integration of clinical trial data and biomarker results in one system which will be further used for clinical biomarker driven trials.
Health economic characteristics of combined testing and treatment strategies will be determined to inform decision makers, using state-of-the-art cost-utility analysis. Optimising the use of current therapy options and avoiding treatments patients will predictably not respond to, may improve cost-utility parameters to levels acceptable for most health systems.
For rapid evaluation of response parameters, the major focus will be on neoadjuvant therapy.
The RESPONSIFY project will lead to validated tests based on formalin-fixed paraffin embedded tissue to predict resistance

Field of science

  • /medical and health sciences/clinical medicine/oncology/cancer
  • /natural sciences/biological sciences/genetics and heredity/genome
  • /medical and health sciences/clinical medicine/oncology/cancer/breast cancer
  • /natural sciences/biological sciences/biochemistry/biomolecules/proteins/proteomics

Call for proposal

FP7-HEALTH-2011-two-stage
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Address
Chariteplatz 1
10117 Berlin
Germany
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 860 580
Administrative Contact
Eveline Fräßdorf (Ms.)

Participants (11)

SIVIDON DIAGNOSTICS GMBH
Germany
EU contribution
€ 664 440
Address
Nattermannallee 1 Geb S19
50829 Koln
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Georg Kox (Dr.)
Diaxonhit SA
France
EU contribution
€ 417 900
Address
Boulevard Massena
75013 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Herve Duchesne De Lamotte (Mr.)
DNA VISION SA
Belgium
EU contribution
€ 397 173
Address
Avenue G Lemaitre 25
6041 Gosselies
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Dimitri Lhoste (Mr.)
UCL Elizabeth Garrett Anderson Institute for Women’s Health
United Kingdom
EU contribution
€ 670 348
Address
Gower Street
WC1E 6BT London
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Greta Borg-Carbott (Ms.)
GBG FORSCHUNGS GMBH
Germany
EU contribution
€ 883 838
Address
Martin Behaim Strasse 12
63263 Neu-isenburg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Lejla Valjevcic (Ms.)
TP21 GMBH
Germany
EU contribution
€ 288 000
Address
Luisenstrasse 14
10117 Berlin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Hanno Wittig (Dr.)
INSTITUT JULES BORDET
Belgium
EU contribution
€ 778 200
Address
Rue Heger Bordet 1
1000 Bruxelles
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Marielle Sautois (Ms.)
INSTITUT GUSTAVE ROUSSY
France
EU contribution
€ 427 000
Address
Rue Camille Desmoulins 39
94805 Villejuif
Activity type
Research Organisations
Administrative Contact
Arnauld Forest (Mr.)
UNIVERSITAT BASEL
Switzerland
EU contribution
€ 325 835,60
Address
Petersplatz 1
4051 Basel
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Matthias Schwenkglenks (Dr.)
KAROLINSKA INSTITUTET
Sweden
EU contribution
€ 276 880
Address
Nobels Vag 5
17177 Stockholm
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Maria Von Witting (Ms.)
F. HOFFMANN-LA ROCHE AG

Participation ended

Switzerland
Address
Grenzacherstrasse 124
4070 Basel
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Stefan Scherer (Dr.)